Lifeward has announced the US launch of the ReWalk 7 Personal Exoskeleton, an advanced personal exoskeleton technology for individuals with spinal cord injuries.
The ReWalk 7, which features cloud connectivity and customisable walking speeds, enhances user experience by offering a functional and personalised walking experience.
It has been developed with input from over two dozen end users and physical therapists, ensuring its effectiveness in both rehabilitative and real-world settings.
The device introduces several advancements, including smoother movement with two customisable walking speeds for seamless indoor and outdoor transitions.
Lifeward CEO Larry Jasinski said: “The ReWalk 7 was developed over several years, integrating advanced technological innovations with feedback from clinicians and patients to build upon the ReWalk’s world-class reputation for industry leadership.
“The result is a device that is optimised for real-world use, with an unmatched user experience and freedom of movement.
“We are thrilled to be able to provide paralysed individuals across the country with a new option for integrating walking to everyday life.”
The exoskeleton also offers improved control through Crutch Control, enabling users to manage walking functions at the touch of a button.
In addition, the new Wrist Control smartwatch and MyReWalk mobile app allow users to select operation modes, set goals, and track usage with ease.
Further enhancements include increased accessibility, with an improved battery allowing for longer walking durations and seamless activation of stairs and curbs.
The ReWalk 7 also features improved training capabilities with a new therapist handheld device and click-to-stop control for safer progression to optimal gait patterns.
Lifeward is currently commercialising ReWalk 7 in the US for both personal and clinical use.
Lifeward Clinical Development Director and usability testing primary investigator Jill Butler said: “The feedback we received from clinicians and ReWalkers was invaluable.
“Therapists felt that the handheld device will make training sessions much easier and more efficient, and ReWalk users were excited about the enhanced level of confidence and control they felt using the new crutch control unit.
“This feedback helped us to optimise the ReWalk to maximise success in real-world environments.”
Last month, ReWalk 7 received the US Food and Drug Administration (FDA) approval, following previous advancements for the ReWalk product line.
